another new IBC review article--this time from MD Anderson
 

new article in terms of publishing--but was presented in Dec 2008 @ first IBC conference

http://www3.interscience.wiley.com/c...7246/HTMLSTART
Supplement
Novel targeted therapies in inflammatory breast cancer
Massimo Cristofanilli, MD * a
Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas
email: Massimo Cristofanilli (mcristof@mdanderson.org)
*Correspondence to Massimo Cristofanilli, Department of Breast Medical Oncology, The University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 1354, Houston, TX 77030

aCurrent address: Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania

The articles in this supplement were presented at the First International Inflammatory Breast Cancer Conference, Houston, Texas, December 5-7, 2008.
Fax: (713) 794-4385
KEYWORDS
inflammatory breast cancer • chemotherapy • HER2 • trastuzumab • lapatinib
ABSTRACT

Inflammatory breast cancer (IBC) accounts for 1% to 5% of all breast cancer cases. Its aggressive biology is characterized by rapid disease progression and poor prognosis. To improve and standardize therapy for IBC, development of novel therapeutics to molecular targets of IBC is key. Trastuzumab treatment, an anti-HER2 humanized monoclonal antibody, has been demonstrated to improve the 3-year survival rate of patients with IBC (70.1% vs 53.3%; P = .0007). Another chemotherapeutic drug, lapatinib, a dual tyrosine inhibitor of epidermal growth factor (EGFR) and HER2 signaling, in combination with capecitabine demonstrated encouraging results, with a 51% decrease in disease progression. Further investigation is needed to confirm the efficacy of lapatinib. Cancer 2010;116(11 suppl):2837-9. © 2010 American Cancer Society.